dr30206
mAbexperimentalTri-specific
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 27, 2023 (NCT06132828)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
- Transforming growth factor beta-2INHIBITOR
TGFB2 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Tri-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07056777 | Phase 1/Phase 2 (Phase 2) | Mar 25, 2025 | Sun Yat-Sen University, Zhejiang Doer Biologics Co., Ltd. |
| NCT06132828 | Phase 1 | Nov 27, 2023 | Huadong Medicine Co., Ltd., Huazhong University of Science and Technology, Zhejiang Doer Biologics Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang Doer Biologics Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Huadong Medicine Co., Ltd. | For profit | 1 | 0 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1